p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours.
The tumour suppressor gene p53 is the gene most often reported to be mutated in clinical cancers with something like half of all tumours harbouring mutations. Further, many studies have suggested that p53 mutations have prognostic importance and sometimes are a significant factor in determining the response of tumours to therapy. The value of knowing the p53 status of individual tumours will increase if currently researched strategies aimed at developing p53-based treatment protocols come to fruition. There are quite a number of techniques used to detect p53 defects in both tumours and in the germline of cancer-prone families, although some of these methods are indirect and each has certain drawbacks. In this brief review we will discuss the value of two assays of p53 function as a means of detecting and partly characterizing p53 mutations. The two assays are the apoptotic assay, which measures the response of peripheral blood lymphocytes to radiation-induced DNA damage and the FASAY, a yeast based assay which assesses the ability of a given p53 protein to transactivate p53 target genes. Both of these assays are rapid, yielding results within 5 days. Further, they not only offer the possibility of detecting p53 mutations but also of characterizing a given mutation in terms of two of p53's most important functions, namely the induction of apoptosis and the transactivation of target genes.
Camplejohn
R S
RS
Richard Dimbleby Department of Cancer Research, Guy's, King's and St Thomas' School of Medicine, King's College, St Thomas' Hospital, London, UK. r.camplejohn@icrf.icnet.uk
Rutherford
J
J
D000483:Alleles; D000818:Animals; D017209:Apoptosis / Q000235:genetics; D001483:Base Sequence; D017931:DNA Primers; D016158:Genes, p53; D018095:Germ-Line Mutation; D006801:Humans; D051379:Mice; D009154:Mutation; D009369:Neoplasms / Q000235:genetics*
D017931:DNA Primers